Adage Capital Partners GP L.L.C. Has $58.82 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Adage Capital Partners GP L.L.C. increased its stake in Regeneron Pharmaceuticals by 109.1%, holding 92,745 shares valued at approximately $58.82 million as of the latest reporting period.
• Regeneron Pharmaceuticals reported $12.89 EPS for the last quarter, surpassing analysts' expectations of $8.43, with revenues reaching $3.68 billion.
• The company has a dividend yield of 0.6%, announcing a quarterly dividend of $0.88 to be paid on September 3rd.

Adage Capital Partners GP L.L.C. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 109.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 92,745 shares of the biopharmaceutical company's stock after buying an additional 48,396 shares during the quarter. Adage Capital Partners GP L.L.C. owned about 0.08% of Regeneron Pharmaceuticals worth $58,822,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after purchasing an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock valued at $1,379,467,000 after purchasing an additional 89,579 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Regeneron Pharmaceuticals by 18.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after purchasing an additional 174,056 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Regeneron Pharmaceuticals by 30.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after purchasing an additional 226,952 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of REGN traded up $6.16 during trading hours on Friday, hitting $573.38. The stock had a trading volume of 959,753 shares, compared to its average volume of 949,804. The company's fifty day moving average is $562.59 and its two-hundred day moving average is $584.62. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,170.58. The stock has a market capitalization of $60.77 billion, a price-to-earnings ratio of 14.45, a P/E/G ratio of 1.90 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 EPS. The company's revenue was up 3.6% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Analyst Ratings Changes

REGN has been the subject of several research analyst reports. Sanford C. Bernstein upped their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Morgan Stanley reissued an "overweight" rating and issued a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.